Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy (eBook)

This book comprehensively examines chemotherapy-induced peripheral neuropathy (CIPN), a common dose-limiting condition that negatively affects both the quality of life of cancer patients and disease outcomes.

CIPN remains a challenging area for both clinical care and research, as there are multiple unresolved issues. Written by leading international experts, the book discusses the natural history of CIPN, the latest predictors of toxicity, instruments for evaluating symptoms, and prevention/therapeutic strategies, as well as patients' experiences of this common clinical syndrome. Lastly it highlights avenues for future research to enhance our understanding of CIPN.

Providing essential information on the management of CIPN and the latest research in the field, this book is a valuable resource for researchers and healthcare providers working with patients with various malignant diseases.

Maryam Lustberg, MD: Dr. Lustberg is an Associate Professor Division of Medical Oncology at The Ohio State University, where she specializes in treating patients with breast cancer and conducts NIH-funded research at Ohio State's Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James). She is chair on the Breast Cancer Survivorship Care Committee and is the Medical Director of Cancer Supportive Care Services. She is the President Elect of Multi National Association of Cancer Supportive Care (MASCC) and serves as  Chair of MASCC Neurological Committee.

Charles L Loprinzi, MD:  Dr. Loprinzi, the endowed Regis Professor of Breast Cancer Research, is a medical oncologist who has been working at Mayo Clinic in Rochester Minnesota since 1985. He has been intimately involved in symptom control research, defined as research aimed at trying to prevent and/or treat and/or better understand symptoms related to cancer and or cancer therapy.  A large part of this work has involved the topic of chemotherapy-induced neuropathy.  Dr. Loprinzi has been intimately involved in the conduct of 8 cooperative group randomized, placebo-controlled, double-blinded, Phase III clinical trials, 4 to try to prevent CIPN and 4 to try to treat established CIPN.  He has more than 50 publications related to chemotherapy neuropathy and has served as the co-chair of the American Society of Clinical Oncology (ASCO) chemotherapy-induced peripheral neuropathy guidelines on two occasions.